---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087013"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:18:02.047943+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics Q2 2024: Cash $269.6M, initiates Phase 1 SLE trial, advances CNTY-101

## Summary
- Initiated Phase 1 CALiPSO-1 trial of CNTY-101 in Systemic Lupus Erythematosus, with protocol amended to include Lupus Nephritis cohort; expects initial data by year-end 2024.
- Presented interim ELiPSE-1 trial data at ASCO showing encouraging efficacy and tolerability in relapsed/refractory B-cell lymphomas; dose escalation completed, dose expansion expected in 2H 2024.
- Ended Q2 2024 with $269.6 million cash, equivalents, and investments; cash runway into 2026. GAAP operating expense guidance $150-$160 million.
- Completed $60 million private placement and acquired Clade Therapeutics in April 2024, enhancing Allo-Evasion platform and adding preclinical αβ iT programs.
- R&D expenses $27.2 million for Q2 2024 vs $22.7 million prior year; net loss $31.2 million vs $33.3 million.

## SEC filing metadata
- accession: 0001104659-24-087013
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465924087013/0001104659-24-087013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465924087013/tm2421030d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087013
- JSON: https://secwatch.observer/filing/0001104659-24-087013.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.